Navigation Links
Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
Date:11/5/2013

therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Forward-Looking Statements Disclaimer
 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the conference call and webcast to discuss financial results. 

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; our lack of commercial sales; our failure to obtain any necessary additional financing; our substantial dependence on the success of our current compounds, AT-001, AT-002 and AT-003, which are still in development; our inability to identify, license, develop and commercialize additional product candidates; our inability  to obtain regulatory approval for our existing or future product candidates;  the lack of commercial success of our current or future product candidates; uncertainties regarding the outcomes of studies regarding our products; effects of competition; our failure to attract and keep senior management and key sc
'/>"/>

SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Aratana Therapeutics Adds To Drug Development Team
6. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
7. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
11. Fate Therapeutics Strengthens Its iPSC Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Senior supply chain management ... associations, addressed the challenges of “Reducing Cost, Lead Time, ... through strategic sourcing. Describing the partnership of the Bio ... Chain Management Institute ( SCMI) of the University ... 24 at the Kroc Institute of Peace and Justice ...
(Date:7/10/2014)... , July 10, 2014 Research and ... of the "International Photonic Integrated Circuit (Monolithic ... to 2019" report to their offering. ... The concept of photonic integration traces its roots ... The promise of photonic integration went unexplored and ...
(Date:7/10/2014)... journal PNAS (Proceedings of the National Academy of ... sleep deprivation have a significant effect on our metabolism. ... best time of day to test for diseases such ... effectively. , Researchers from the University of Surrey and ... between sleep deprivation, body clock disruption and metabolism, and ...
(Date:7/10/2014)... out for crude 3-D glasses, polarized glasses, and ... basic devices, used to trick the brain into ... rendered obsolete with the introduction of new holography ... TAU doctoral students Yuval Yifat, Michal Eitan, and ... on nanoantennas that could be used for security ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China ... develops, manufactures, and markets specialty pharmaceutical products in ... completed Phase I clinical trials of its novel ... to be the most widely prescribed class of ...
... SAN DIEGO, Sept. 22 Marshall Edwards, Inc. (Nasdaq: ... development of novel anti-cancer therapeutics, announced today that Daniel P. ... update on Marshall Edwards and its novel oncology programs at ... beginning at 4:30 p.m. EDT from the New York Palace ...
... Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to... -- HOERSHOLM, Denmark and SAN DIEGO, Sept. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 2Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 3Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 5Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 6Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 7Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 8Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 9Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 10
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... http://www.ptitime.com ), an established leader in manufacturing Time ... Generation II,an innovative biometric system that features a ... generation of Pyramid,s TimeTrax Bio was,released in January ... same,features as its predecessor with one-touch time and ...
... of "New Employee,Verification Act", ALEXANDRIA, Va., May ... resource management today led a coalition of,business leaders ... Act." In testimony today before the House Ways ... and CEO of SHRM,urged legislators to recognize that ...
... Chicago, Ill. May 6, 2008 A recent study ... dramatically between 1990 and 2005, but that they continue to ... products contributes nearly one-third of total mercury emissions to the ... into the relative magnitudes of the different sources of mercury ...
Cached Biology News:Pyramid Launches TimeTrax Bio Generation II 2SHRM CEO Testifies Before House Subcommittee on Social Security 2SHRM CEO Testifies Before House Subcommittee on Social Security 3Study shows mercury levels from products decreasing, though still at dangerous levels 2
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
A trigger solution for Flashlight labeled materials....
... The MiniOpticon 2-color real-time PCR detection system holds 48 ... array of 48 LEDs independently excites fluorescence (470-500 nm) ... detects emitted light (523-543 nm and 540-700 nm). This ... MJ Mini thermal cycler. System dimensions are 18 x ...
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
Biology Products: